IsomiR stoichiometry changes as disease biomarkers

Despite substantial research interest over the past decade, microRNAs (miRNAs) have not yet succeeded in reaching their potential as non-invasive diagnostic biomarkers. One key hindrance to their use is the lack of disease specificity of single miRNAs, combined with variable baseline expression between individuals. In the current work, we sought to leverage variations of the stoichiometry of miRNA isoform variants, or isomiRs, to expand the pool of potential miRNA biomarkers and facilitate normalization of their expression, using one isoform to normalize expression of another from the same miRNA. Although isomiRs are often still overlooked in miRNA biomarker studies, we show that analysis at the isoform level reveals many putative biomarkers that are missed when aggregating all isomiRs by their miRNA of origin and demonstrate, as proof-of-principle, that changes in isomiR stoichiometry can act as biomarkers for inflammation and COVID-19 infection with high accuracy and precision. Our findings collectively present a case to analyze variations of isomiR stoichiometry to broaden the use of miRNAs as biomarkers, and we additionally provide a novel method of identifying putative isomiR biomarkers that offers the benefit of built-in normalization.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Nucleic Acids
Published
2025-05-24
DOI
https://doi.org/10.1016/j.omtn.2025.102578
Primary Topic
MicroRNA in disease regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IsomiR stoichiometry changes as disease biomarkers

Linden J. Gearing, Michael Paul Gantier, Katherine A. Pillman, Alexandra L. McAllan
Molecular Therapy — Nucleic Acids
MicroRNA in disease regulation
article

IsomiR stoichiometry changes as disease biomarkers

Linden J. Gearing, Michael Paul Gantier, Katherine A. Pillman, Alexandra L. McAllan
article en

Abstract

Despite substantial research interest over the past decade, microRNAs (miRNAs) have not yet succeeded in reaching their potential as non-invasive diagnostic biomarkers. One key hindrance to their use is the lack of disease specificity of single miRNAs, combined with variable baseline expression between individuals. In the current work, we sought to leverage variations of the stoichiometry of miRNA isoform variants, or isomiRs, to expand the pool of potential miRNA biomarkers and facilitate normalization of their expression, using one isoform to normalize expression of another from the same miRNA. Although isomiRs are often still overlooked in miRNA biomarker studies, we show that analysis at the isoform level reveals many putative biomarkers that are missed when aggregating all isomiRs by their miRNA of origin and demonstrate, as proof-of-principle, that changes in isomiR stoichiometry can act as biomarkers for inflammation and COVID-19 infection with high accuracy and precision. Our findings collectively present a case to analyze variations of isomiR stoichiometry to broaden the use of miRNAs as biomarkers, and we additionally provide a novel method of identifying putative isomiR biomarkers that offers the benefit of built-in normalization.

Molecular Therapy — Nucleic AcidsVol. 36(3)
South Australia Pathology (AU), University of South Australia (AU), Hudson Institute of Medical Research (AU), Centre for Cancer Biology (AU), Monash University (AU), The University of Adelaide (AU)
Department of Health, State Government of Victoria
Zero hunger
Openalex Percentile: Top 84%
MicroRNA in disease regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.